MC4R Agonists: Structural Overview on Antiobesity Therapeutics

Area of Science:

• Pharmacology
• Endocrinology
• Metabolic Diseases

Background:

• The melanocortin-4 receptor (MC4R) is a key regulator of energy homeostasis and adipose tissue formation.
• MC4R is a promising monogenic target for novel antiobesity therapeutics.
• Previous clinical trials of MC4R agonists were hampered by undesirable side effects.

Purpose of the Study:

• To compile potent MC4R agonists.
• To discuss structural differences influencing MC4R selectivity over other melanocortins.
• To provide insight into recent progress and future directions for MC4R agonist development.

Main Methods:

• Literature review and compilation of published MC4R agonists.
• Analysis of structural characteristics of diverse agonist classes (linear peptides, cyclic peptides, small molecules).
• Comparative analysis of selectivity profiles for MC4R over other melanocortin receptors.

Main Results:

• Identified several potent and selective MC4R agonists with diverse chemical structures.
• Highlighted key structural features contributing to MC4R selectivity.
• Observed that while in vitro efficacy is achievable, clinical translation faces challenges due to side effects.

Conclusions:

• Structural modifications are crucial for achieving high MC4R selectivity and potentially mitigating side effects.
• Further research into MC4R agonist structure-activity relationships is warranted.
• Development of novel MC4R agonists requires careful consideration of chemical structure and selectivity for therapeutic success.